Shield Diagnostics Group, plc
This article was originally published in The Gray Sheet
Executive Summary
Raises about $3.8 mil., net of expenses, in private placement of 499,361 new ordinary shares with institutional investors. Proceeds are tabbed for further commercialization of the Dundee, UK firm's Afecta (Activated Factor XII) and homocysteine cardiovascular tests, "including the development of new point-of-care diagnostics," the company states. The placement was arranged by Nomura International, plc